Display options
Cite
Seiffge DJ, Meinel T, Purrucker JC, et al. Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. J Neurol Neurosurg Psychiatry. 2021;92(5):534-541doi: 10.1136/jnnp-2020-325456.
Seiffge, D. J., Meinel, T., Purrucker, J. C., Kaesmacher, J., Fischer, U., Wilson, D., & Wu, T. Y. (2021). Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. Journal of neurology, neurosurgery, and psychiatry, 92(5), 534-541. https://doi.org/10.1136/jnnp-2020-325456
Seiffge, David J, et al. "Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants." Journal of neurology, neurosurgery, and psychiatry vol. 92,5 (2021): 534-541. doi: https://doi.org/10.1136/jnnp-2020-325456
Seiffge DJ, Meinel T, Purrucker JC, Kaesmacher J, Fischer U, Wilson D, Wu TY. Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. J Neurol Neurosurg Psychiatry. 2021 May;92(5):534-541. doi: 10.1136/jnnp-2020-325456. Epub 2021 Feb 04. PMID: 33542084; PMCID: PMC8053326.
Copy Download .nbib Format: NLM
Share it on

J Neurol Neurosurg Psychiatry. 2021 May;92(5):534-541. doi: 10.1136/jnnp-2020-325456. Epub 2021 Feb 04.

Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants.

Journal of neurology, neurosurgery, and psychiatry

David J Seiffge, Thomas Meinel, Jan Christoph Purrucker, Johannes Kaesmacher, Urs Fischer, Duncan Wilson, Teddy Y Wu

Affiliations

  1. Stroke Research Center, Queen Square Institute of Neurology, London, UK [email protected].
  2. Department of Neurology, Inselspital University Hospital Berne, Bern, Switzerland.
  3. Neurology, Heidelberg University Hospital, Heidelberg, Germany.
  4. University Institute of Diagnostic and Interventional of Neuroradiology, University Institute of Diagnostic, Interventional and Pediatric RadiologyUniversity Institute of Diagnostic and Interventional of Neuroradiology, University Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital Bern, Bern, Switzerland.
  5. Stroke Research Center, Queen Square Institute of Neurology, London, UK.
  6. Neurology, Christchurch Hospital, Christchurch, New Zealand.
  7. New Zealand Brain Research Institute, Christchurch, New Zealand.

PMID: 33542084 PMCID: PMC8053326 DOI: 10.1136/jnnp-2020-325456

Abstract

Direct oral anticoagulants (DOACs) have emerged as primary therapeutic option for stroke prevention in patients with atrial fibrillation. However, patients may have ischaemic stroke despite DOAC therapy and there is uncertainty whether those patients can safely receive intravenous thrombolysis or mechanical thrombectomy. In this review, we summarise and discuss current knowledge about different approaches to select patient. Time since last DOAC intake-as a surrogate for anticoagulant activity-is easy to use but limited by interindividual variability of drug pharmacokinetics and long cut-offs (>48 hours). Measuring anticoagulant activity using drug-specific coagulation assays showed promising safety results. Large proportion of patients at low anticoagulant activity seem to be potentially treatable but there remains uncertainty about exact safe cut-off values and limited assay availability. The use of specific reversal agents (ie, idarucizumab or andexanet alfa) prior to thrombolysis is a new emerging option with first data reporting safety but issues including health economics need to be elucidated. Mechanical thrombectomy appears to be safe without any specific selection criteria applied. In patients on DOAC therapy with large vessel occlusion, decision for intravenous thrombolysis should not delay thrombectomy (eg, direct thrombectomy or immediate transfer to a thrombectomy-capable centre recommended). Precision medicine using a tailored approach combining clinicoradiological information (ie, penumbra and vessel status), anticoagulant activity and use of specific reversal agents only if necessary seems a reasonable choice.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords: cerebrovascular disease; stroke

Conflict of interest statement

Competing interests: DJS: advisory board: Bayer and Pfizer (manufacturer of Rivaroxaban and Apixaban); personal fees used for research funding: Portola (manufacturer of Andexanet alfa). Research fundi

References

  1. Blood Adv. 2020 Feb 25;4(4):728-739 - PubMed
  2. JAMA. 2012 Jun 27;307(24):2600-8 - PubMed
  3. Crit Care. 2017 Feb 15;21(1):32 - PubMed
  4. Stroke. 2016 Apr;47(4):1127-30 - PubMed
  5. Ann Neurol. 2018 Mar;83(3):451-459 - PubMed
  6. Stroke. 2018 Mar;49(3):e46-e110 - PubMed
  7. Acta Neuropathol. 2018 Mar;135(3):311-336 - PubMed
  8. Lancet. 2016 Apr 23;387(10029):1723-31 - PubMed
  9. Stroke. 2015 Dec;46(12):3536-9 - PubMed
  10. Stroke. 2015 Oct;46(10):2741-7 - PubMed
  11. Circulation. 2017 Mar 14;135(11):1024-1035 - PubMed
  12. Stroke. 2010 Oct;41(10):2348-52 - PubMed
  13. Eur J Neurol. 2018 May;25(5):747-e52 - PubMed
  14. Expert Opin Investig Drugs. 2007 Apr;16(4):431-40 - PubMed
  15. Pathology. 2013 Jun;45(4):435-7 - PubMed
  16. J Stroke. 2017 Sep;19(3):347-355 - PubMed
  17. Ann Neurol. 2013 Aug;74(2):266-74 - PubMed
  18. J Neurol. 2019 Nov;266(11):2807-2811 - PubMed
  19. J Thromb Thrombolysis. 2017 Jan;43(1):112-116 - PubMed
  20. Stroke. 2017 Jun;48(6):1608-1616 - PubMed
  21. Stroke. 2020 Jul;51(7):e130-e131 - PubMed
  22. J Stroke. 2018 Sep;20(3):321-331 - PubMed
  23. N Engl J Med. 2020 May 21;382(21):1981-1993 - PubMed
  24. Lancet. 2014 Nov 29;384(9958):1929-35 - PubMed
  25. Am J Clin Pathol. 2016 Sep;146(3):378-83 - PubMed
  26. Stroke. 2018 Sep;49(9):2237-2240 - PubMed
  27. Stroke. 2020 Mar;51(3):892-898 - PubMed
  28. Ann Neurol. 2020 Feb 12;: - PubMed
  29. Int J Stroke. 2016 Oct;11(7):748-58 - PubMed
  30. Eur J Neurol. 2014;21(1):e3-4 - PubMed
  31. Circulation. 2015 Sep 29;132(13):1261-9 - PubMed
  32. Thromb Haemost. 2018 Mar;118(3):437-450 - PubMed
  33. Neurology. 2020 Feb 25;94(8):e842-e850 - PubMed
  34. Ann Neurol. 2019 Nov;86(5):770-779 - PubMed
  35. Stroke. 2017 Jul;48(7):2031-2033 - PubMed
  36. Thromb Haemost. 2013 Jul;110(1):153-61 - PubMed
  37. Cerebrovasc Dis. 2018;46(5-6):193-199 - PubMed
  38. N Engl J Med. 2019 Apr 4;380(14):1326-1335 - PubMed
  39. Eur Stroke J. 2019 Dec;4(4):307-317 - PubMed
  40. Can J Cardiol. 2013 Jul;29(7 Suppl):S24-33 - PubMed
  41. Ann Neurol. 2021 Jan;89(1):42-53 - PubMed
  42. Chest. 2017 Jan;151(1):127-138 - PubMed
  43. Stroke. 2020 May;51(5):1616-1619 - PubMed
  44. J Neurol Sci. 2017 Aug 15;379:207-211 - PubMed
  45. Clin Res Cardiol. 2013 Jun;102(6):399-412 - PubMed
  46. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2479-2483 - PubMed
  47. Stroke. 2009 Nov;40(11):3547-51 - PubMed
  48. Stroke. 2020 Feb;51(2):533-541 - PubMed
  49. Neurology. 2020 May 12;94(19):e1968-e1972 - PubMed
  50. Stroke. 2017 Jan;48(1):152-158 - PubMed
  51. Ann Neurol. 2012 May;71(5):624-33 - PubMed
  52. J Neurol. 2017 Jun;264(6):1227-1235 - PubMed
  53. Eur Stroke J. 2019 Jun;4(2):181-188 - PubMed
  54. Ann Neurol. 2018 Jul;84(1):89-97 - PubMed
  55. Neurology. 2020 May 12;94(19):811-812 - PubMed
  56. J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2685-93 - PubMed
  57. Cerebrovasc Dis. 2019;48(1-2):17-25 - PubMed
  58. Int J Stroke. 2020 Aug;15(6):609-618 - PubMed
  59. Stroke. 2019 Dec;50(12):e344-e418 - PubMed
  60. N Engl J Med. 2015 Aug 6;373(6):511-20 - PubMed
  61. Eur Stroke J. 2019 Mar;4(1):6-12 - PubMed
  62. Stroke. 2014 Mar;45(3):896-9 - PubMed
  63. J Stroke Cerebrovasc Dis. 2019 Mar;28(3):815-820 - PubMed
  64. PLoS One. 2011;6(10):e26087 - PubMed
  65. J Stroke Cerebrovasc Dis. 2019 Mar;28(3):768-773 - PubMed

Publication Types